Freedom to choose your connected pump
Connected pumps
iLet Bionic Pancreas
The iLet Bionic Pancreas reduces the need to make decisions about your diabetes management by automatically adjusting to your insulin needs based on your Dexcom G7 and Dexcom G7 15 Day readings. Setup is easy with only your weight required to get started, and as the iLet learns about you, no carb counting† and no corrections are needed.
Dexcom G7 15 Day is for use in adults 18+
The Tubeless Omnipod® 5 Automated Insulin Delivery System
The only tubeless automated insulin delivery system that integrates with Dexcom G7 and Dexcom G7 15 Day. Omnipod 5‡ is a waterproof,§ wearable alternative to traditional pumps, and can now be controlled using your iPhone,|| Android phone,|| or the Insulet provided Controller. SmartAdjust™ technology proactively helps to correct high and protect from low glucose levels.¶,4,#,5
The Tandem Mobi System
Tandem Mobi is impressively small and can be worn almost anywhere** giving you more freedom and options for managing your diabetes. Powered by Control-IQ+ and controllable with a compatible, personal iPhone,|| it integrates with Dexcom G7 for predictive alerts and more time in range, all without fingersticks.††
Dexcom G7 15 Day compatibility coming in early 2026
††Fingersticks required for diabetes treatment decision if symptoms or expectations do not match readings.
††Fingersticks required for diabetes treatment decision if symptoms or expectations do not match readings.
Tandem t:slim X2TM insulin pump
The t:slim X2 insulin pump is an all-in-one system that features a sleek and modern color touchscreen. Easy to use and holding up to 300 units of insulin, it’s powered by Control-IQ+ with AutoBolus—which is designed to prevent highs1 and cover missed meal boluses.
Dexcom G7 15 Day compatibility coming in early 2026
“Quinn is thriving in her diabetes management journey, thanks to her Dexcom G7 seamlessly integrating with her AID system. She enjoys the 30-minute warmup time and the smaller sensor size. We appreciate the Clarity card for its valuable insights and trends, helping to keep Quinn in range and feeling her best.”
- Parents of Quinn L., Dexcom Warrior
Meet Dexcom G7 systems
Dexcom G7 and Dexcom G7 15 Day offer powerful glucose monitoring that’s made for connections, letting you view your glucose data on any compatible smart device.||
Dexcom G7 15 Day is for use in adults 18+
Our experts are here to help.
*To learn more about insulin pump integrations and compatibility with Dexcom CGM Systems, visit dexcom.com/integrate. †User must be carb aware. ‡Pod shown without the necessary adhesive. §The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Personal Diabetes Manager is not waterproof. The Dexcom G7 sensor is waterproof and may be submerged under eight feet of water for up to 24 hours without failure when properly installed. ||Smart device sold separately. To view a list of compatible devices, visit dexcom.com/compatibility. ¶Study in 240 people with T1D aged 6-70 years involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time with high blood glucose in adults/adolescents and children, standard therapy vs. 3-month Omnipod 5: 32.4% vs. 24.7%; 45.3% vs. 30.2%. Median time with low blood glucose in adults/adolescents and children, standard therapy vs. 3-mo Omnipod 5: 2.0% vs. 1.1%; 1.4% vs. 1.5%. #Study in 80 people with T1D aged 2 - 5.9 yrs involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time with high blood glucose (>180mg/dL) from CGM in standard therapy vs Omnipod 5 = 39.4% vs. 29.5%. Average time with low blood glucose (<70mg/dL) from CGM in standard therapy vs Omnipod 5 = 3.41% vs. 2.13%. **Do not wear or place your pump more than 12 inches (30.5 cm) above your infusion site. Doing so may result in over delivery of insulin.
1 Brown SA, et al. N Engl J Med. 2019;381(18):1707-1717. 2 Brown SA et al. Diabetes Care. 2021;44(7):1630-1640. 3 Russell SJ, et al. N Engl J Med. 2022;387(13):1161-1172. 4 Brown et al. Diabetes Care. 2021;44(7):1630-1640. 5 Sherr JL, et al. Diabetes Care. 2022;45(8):1907–1910.
BRIEF SAFETY STATEMENT: Failure to use the Dexcom Continuous Glucose Monitoring System and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the Dexcom CGM do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency.